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SUMMARY
Swiss female mice (25-30 g; n = 100) were four times treated i.p. with busulphan (20 mg/kg), with 15 day interval 
between doses. Blood was collected by retroorbital puncture from treated and non treated control animals (n = 15) for 
white blood cell count, hematocrit and hemoglobin evaluation, before treatment and on 30th, 60th, 90th days following 
the first dose of the drug. On day 60 both treated (60 survived animals) and non treated (n = 15) animals received 
intermuscular implant of demineralized bone matrix (DBM-10 mg). All of them were killed 30 days after implant (90th 
day post busulphan initial dose) for histological analysis of esternal bone marrow (EBM) and ectopic osteomyelogenous 
response to the DBM implant. Thirty days after the first dose of busulphan, leukopenia and drop in the granulocyte, 
lymphocyte and monocyte numbers were observed. The hematocrit and hemoglobin rate decreased on 60th day. 
Histologycal analysis of the EBM of the test group showed hypocellularity, sinusoid capilar distention and reduction in 
megakaryocyte numbers. Control animals showed 100% positive response to DBM implant with the formation of 
metaplastic plaques made of bone trabeculae forming cavities filled with haematopoietic cells. 46.7% of the test 
animals had positive osteomyelogenous response, similar to that of the control groups, except for hypocellularity and 
more adipocytes; 25% displayed late and incomplete response with predominance of cartilaginous component, less 
neoformed bone tissue and absence of haematopoietic cells; the remaining 28.3% did not respond at all.
UNITERMS: Demineralization; Bones; Busulphan.
IN T R O D U C T IO N
A dministration of high doses of busulphan, a cytostatic agent, for long periods, ends in hypoplasia or aplasia of the bone marrow. This occurs due to a 
permanent damage of the stem cells, jeopardizing their 
capacity to proliferate and differentiate haematopoietic cell 
lineages resulting in pancytopenia (Morley; Blake", 1974; 
Morley et a l 1975; Trainor; Morley'6, 1976; Pugsley et 
al.'0, 1978).
The intermuscular implant of demineralized bone matrix 
(DBM) in mice leads to the appearing of metaplasic 
osteomyelogenous plaques within 30 days, with haematopoiet­
ic component physiologically and morphologically similar 
to the autologous marrow of the implanted animal (Urist; 
Strates20, 1971; Reddi; Huggins12, 1972; Urist; C raven19, 
1980). The whole process is triggered by a morphogenetic 
protein (Bone Morphogenetic Protein-BMP) associated to 
the collagen of calcified tissues (Urist; Strates20, 1971; 
Nilsson et a l 1986).
The aim of this study was to analyse the ectopic 
osteomyelogenic response induced by intermuscular DBM 
implant in busulphan-treated mice.
M A T E R IA L  A N D  M E T H O D
Demineralized bone matrix (DBM) preparation
For the DBM preparation femur and tibia diaphyses were 
obtained from male and female mice. They were killed by 
prolonged ether inhalation, bones collected and soft tissues 
discarded. The material was processed according to Urist’s'8 
technique (1973) slightly modified by Iderhia et al.' (1984).
DBM implant
Under light anesthesia with ether, animals were placed in 
lateral decubitus and after antisepsis with iodinated alcohol, 
a 1.5 cm incision was done in the left thigh skin and fascia. 
10.0 mg of DBM was then put between biceps crural and 
lateral vastus muscles.
DBM efficiency evaluation
DBM efficiency in inducing ectopic osteomyelogenesis 
was previously tested through an intermuscular implant in 
naive animals (n = 15). Thirty days after DBM implant, the 
animals were killed by prolonged ether inhalation, and metaplasic 
plaques collected, fixed in Bouin’s solution and processed 
according to standard histologic technique sections (6 um)
144
MORAES, J.R.E.; M ORAES, F.R.; SANTANA, A.E. Ectopic osteom yelogenous response to dem ineralized bone matrix implant in busulphan treated mice. Braz. J. vet. Res. anim. Sci.
São Paulo, v.33, n.3, p. 144-148, 1996.
embedded in paraffin and stained with hematoxilin-eosin.
Busulphan treatment
Swiss, virgin, female mice (n = 100), weighing 25 to 30 g 
were treated intraperitonially with 20 mg/kg of busulphan 
(Myleram-Welcome) given four times with fortnight interval 
between doses. Busulphan tablets were macerated, diluted 
and homogenized in a fresh water-acetone solution (4:1). 
From 100 treated animals 40 died and 60 were used for 
DBM implants. Control group (n = 15) received equal 
volume of diluent solution.
Hematologic evaluation
During treatment with busulphan, leukogram, hemoglobin 
and hematrocit rates from both test and control groups were 
evaluated at 30 day intervals until the 90lh day following the 
imunosupressant drug injection. Blood samples were taken 
from retroorbital plexus, diluted 1:20 in Turks' solution and 
total leukocyte numbers counted in Neubauer’s chamber. 
Differential leukocyte counting was performed on 
panchromatically stained smears. Hematocrit rates were 
obtained by centrifugation of blood samples in capilar tubes 
for microhematocrit. Hemoglobin value was determined 
through the cianomethahemoglobin method, and optical 
density of the solution was evaluated through spectophotometry 
(Coleman-295).
Ectopic osteomyelogenic response in both control and 
treated animals
Ninety days after initial treatm ent with the 
immunosupressor and 30 days after the DBM implant, 
animals from both test and control groups were killed and 
metaplasic plaques or similar in the implant site were 
surveyed. The plaques, as well as the sternum, were taken 
out and processed for histological evaluation as was 
described elsewhere.
Results were considered positive when the metaplasic 
plaques presented newly formed bone trabeculae with 
marrow cavities filled with haemopoietic tissue and absence 
of cartilaginous tissue. This is similar to the observed in the 
DBM efficiency evaluation in naive animals. Plaques with 
predominance of cartilaginous tissue over bone component 
and rare or absent haematopoietic tissue, were considered 
positive but with incomplete and of late development. 
Implants were considered negative when connective tissue 
capsule was formed surrounding the implanted DBM in the 
absence of cartilaginous, bone or haematopoietic tissues.
The sternum bone marrow evaluation was done by 
analysing haematopoietic cell population and its possible 
relation to busulphan’s effect.
Statistical analysis
The results were analysed statistically through variance of
Figure 1
Effect of busulphan- 
treatment upon circulating 
leukocytes.
(A) total leukocytes;
(B) lymphocytes;
(C) granu locytes;
(D) monocytes.
(o) control animal (n = 15);
(•) treated animals (n = 60).
The results are means and SEM. 
(*) significant difference  
(p<0.05) in relation to control 
group
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means (p<().()5) and by Tuckey’s test (Snedecor; Cochran15, 
1974).
R E SU L T S  
Effect of treatment with busulphan upon circulating blood
Leukopenia with significant cell decrease (p<().()5) was 
observed 30 days after the first dose of the drug, progressed 
and lasted until 9"' day (Fig. 1A). Lymphocytopenia, 
(p<().()5) which also lasted until the 90"' day (Fig. IB), 
reduction in the granulocyte numbers 30 days after the 
initial treatment, worsening on the 60’" day, and a mild 
recovery on the 90"’ day (Fig. 1C), monocytopenia (p<0.05) 
on the 60"’ day following the first dose of busulphan (Fig.
I D), were the blood leukocyte disturbances observed.
As to hematocrit values, there was a significant difference
F ig u re  2
Effect of busulphan-treatment upon hematocrit (A) 
and hemoglobin rate (B). (o) control animals (n = 15); 
(•) treated animals (n = 60). The results are means 
and SEM. (*) significant difference (p<0,05) in rela­
tion to control group.
(p<0.()5) between the test and control groups only on 60"' 
day (Fig. 2A). Hemoglobin levels of the test group had 
significant (p<0.05) decrease on the 60"' and 90"' days with 
a slight recovery on the 90"' day (Fig. 2B).
Effect of busulphan treatment upon bone marrow
The histologic study of the EBM of treated animals 90 
days after the first dose of busulphan showed hypocellularity, 
sinusoid capillar dilation and a significant (p<().()5) reduction 
(50%) on megakaryocyte numbers (control: 10.92±0.36; 
test: 4.38±0.67). Many of them showed karyolysis signs.
DBM efficiency evaluation
All of the test animals showed plaque formation, that was 
comprised by trabeculae of bone tissue forming caviiies 
filled by haematopoietic tissue, similar to that of the sternal 
bone marrow (EBM) and without any cartilaginous tissue.
Response to DBM implant
Control animals
Thirty days after the intermuscular DBM implant a 
positive response was observed in all of the control animals, 
with formation of metaplasic plaques of bone trabeculae in 
which haematopoietic cells-filled cavities were seen. No 
cartilaginous tissue was observed. These results were 
similar to those observed in (lie DBM efficiency evaluation 
in naive animals.
Test animals
Sixty animals survived to the toxic effects of busulphan. 
Among them 28 (46.7%) had a posilive response - similar to 
that observed in the control group - to ihe intermuscular 
implant of DBM. The haematopoietic tissue forming the 
ectopic bone marrow showed hypocellularity, sinusoid 
capillar dilation and moderate numbers of adipose tissue. In 
other 15 animals (25%) from this group, even though 
metaplasic plaque formation ocurred, it was incomplete, 
with less neoformed bone tissue, predominance of cartilaginous 
tissue and absence of haematopoietic components. This 
response also considered delayed, once at that same time (30 
days), in control animals, there was a predominance of bone 
trabeculae, forming haematopoietic component-filled cavities 
and absence of cartilaginous tissue.
In the remaining 17 animals (28.3%), just a fibroblastic 
reaction around DBM particles was observed. There was no 
cartilaginous, bone or haematopoietic tissue formation. This 
response pattern was considered negative.
D I S C U S S IO N
The evident reduction of white blood cells due to the toxic
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effect of busulphan, as previously referred by Morley; B lake'6 
(1974), was also observed in the surviving mice of 
experimental group. Lymphocytopenia seems to be the 
main determinant of leukopenia, even though lymphocytes 
were the predominant white blood cell type found in the 
peripheral blood. The earlier decrease of leukocyte number 
observed on the 30"' day, when compared to the data of 
Iderhia et al.3 (1984), could be explained by the fact that they 
carried out first hematological examination only on the 55"’ 
day post busulphan treatment, so that any precocious 
alterations could be observed by them. Moreover, treatment 
schedule modifications were introduced in the present work: 
while Iderhia et a I.' (1984) used 3 doses of 20 mg/kg and I 
of 10 mg/kg with 15 day interval among them, followed by 
a 5lh dose of 20 mg/kg on the 105"'day, 4 doses of 20 mg/kg 
with 15 day intervals were used in this work.
Hematrocit and hemoglobin values decrease, as well as 
histological alterations like hypocellularity, sinusoid dilation 
and decrease on megakariocyte number - observed on EBM 
of treated mice - essentially proved the effect of busulphan 
causing permanent lesion of stems cells, as referred by 
Morley; Blake7 (1975). Some evidence exists that the colony, 
forming units which survive the treatment, loose their 
proliferating and maturation capacity (Dun; Elson2, 1970). 
The formation of metaplasic plaques of bone and 
haematopoietic tissue observed by Urist17 (1965) and Bang; 
Urist1 (1967) was essentially the same as observed in all 
control rats in the present case. On the other hand, the 
intermuscular implant of DBM in busulphan treated animals 
resulted in a positive response in about half of the animals
from experimental group on day 30 post treatment. Ectopic 
marrow tissue was hypocellular and with higher rate of 
adipocytes than in the control animals.
As could be expected, formation of BMP and haematopoietic 
tissue occurred within 30 days after intermuscular implant of 
DBM in all control animals, in the same way as observed by 
other authors (Urist17, 1965; Bang; Urist1, 1967; Urist; 
Strates20, 1971; Reddi; H u g g in s 12, 1972; Reddi; Anderson", 
1976; Wlodarski; Jacobsiak21, 1978; Iderhia et al.3, 1984; 
Santana14, 1988; Moraes; Moraes4, 1993). On the other hand, 
only 46.7% of treated mice showed weak positive response, 
comprised by hypocellular marrow with high number of 
adipocytes. The higher rate of complete osteomyelogenic 
plaques formation and earlier response seen by the authors, 
when compared to the results obtained by Iderhia et al.3 
(1984), were probably related to the difference of protocol 
introduced in the present research, that is, busulphan doses 
and intervals between each one. The m ost important 
difference introduced was the time when DBM implant was 
carried on: 60 days after first treatment, in opposition to 135 
days referred by them. Earlier implant may result in more 
effective osteomyelogenic response. This could be explained 
by the fact that mononuclear phagocytes play an important 
role in heterotopic ossification induced by DBM that leads 
to the production of factors influencing its development 
(Sakata; Takagi13, 1986; Moraes; Moraes4, 1993). Therefore, 
busulphan-induced leukopenia may interfere directly in the 
successful implant of DBM, that is, the least number of 
leukocytes, specifically monocytes, the smaller is the probability 
of induction of heterotopic ossification.
RESUMO
Camundongos Swiss, fêmeas, (25-30 g; n = 100) receberam 4 injeções de bussulfano (20 mg/kg, ip) a intervalos de 
15 dias (n = 100). Antes do tratamento e após 30, 60 e 90 dias, os animais deste e de um grupo controle (n = 15) foram 
avaliados quanto ao leucograma, taxa de hemoglobina e hematrócito por meio do sangue colhido por punção 
retroorbital. Sessenta dias após o início do tratamento, 60 animais sobreviventes do grupo tratado e 15 animais do 
grupo controle receberam implantes intermuseulares de matriz óssea desmineralizada (MOD-10 mg). No 90s dia (30 
dias após o implante) foram sacrificados para exame histológico da medula óssea esternal (MOE) e da resposta 
osteomielogênica ao implante de MOD. Trinta dias após o início do tratamento observou-se leucopenia, com 
diminuição do número de granulócitos, linfócitos e monócitos nos animais que receberam bussulfano. O hematócrito 
e a taxa de hemoglobina apresentaram-se diminuídos no 609 dia. O exame histológico da MOE do grupo tratado 
revelou hipocelularidade, dilatação dos capilares sinusóides e redução do número de megacariócitos (50%). Os 
animais controle apresentaram 100% de resposta positiva ao implante de MOD, havendo formação de placas 
metaplásicas compostas por trabéculas ósseas contendo cavitações preenchidas por células hematopoiéticas. Em 
46,7% dos animais tratados observou-se resposta osteomielogênica semelhante à do grupo controle, mas com 
hipocelularidade e maior componente de adipócitos; 25% apresentaram resposta osteomielogênica tardia e 
incompleta com menor componente ósseo, maior componente cartilaginoso e ausência de células hematopoiéticas; 
nos 28,3% restantes a resposta foi negativa.
UNITERMOS: Ossos; Desmineralização; Bussulfano.
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